Key facts
- Notable investors include EcoPro Partners, Ice Square Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Medians (Pharmaceuticals)
- ·The full record, as it builds
Funding rounds
No funding rounds for Medians (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medians (Pharmaceuticals)
Manufacturer of natural health products designed for dietary supplementation. The company utilizes processes such as extraction, concentration, separation, fermentation, enzyme conversion, and engineering to develop and produce functional foods, health supplements, food ingredients, and natural drugs with low side effects, enabling consumers to access safe and valuable products that contribute to a healthy life.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Chuncheon, South Korea
- Website
- mediense.co.kr/
- Ownership
- Privately Held (backing)
Medians (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medians (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medians (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.